Johnson & Johnson (JNJ) announced that it has submitted a regulatory filing with the FDA seeking approval for the use of a subcutaneous (SC) induction regimen of its blockbuster immunology medicine Tremfya (guselkumab) in ulcerative colitis (UC) indication.The FDA recently approved Tremfya to treat adults with moderately to severely active UC as both an induction and maintenance therapy. However, the induction dose of the drug can only be administered as an intravenous (IV) therapy. The maintenance dose of ...